Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CLPP | Q16740 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PRLHR | P49683 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424334 | 0.89 | HPGD (0.46) | MTHFD2MAPK1HPGDCLPPPKM | |
| SCHEMBL22424053 | 0.82 | MTHFD2 (0.52) | MTHFD2HPGDPKM | |
| SCHEMBL22423998 | 0.82 | CLPP (0.60) | MTHFD2HPGDCLPPPKM | |
| SCHEMBL22424504 | 0.81 | PRLHR (0.41) | MTHFD2MAPK1CLPPPRLHR | |
| SCHEMBL24275996 | 0.79 | PRLHR (0.43) | MTHFD2PRLHR | |
| SCHEMBL22424333 | 0.78 | CLPP (0.54) | HPGDCLPPPRLHR | |
| SCHEMBL22424063 | 0.78 | MTHFD2 (0.50) | MTHFD2HPGDPKM | |
| SCHEMBL24276008 | 0.72 | P2RX7 (0.39) | MAPK1PRLHR | |
| SCHEMBL22423967 | 0.70 | P2RX7 (0.41) | HPGD | |
| SCHEMBL22424050 | 0.70 | HPGD (0.48) | MTHFD2HPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |